New Drug Targets/Epigenetic Changes Found in Cocaine Addiction

Researchers from the Icahn School of Medicine at Mount Sinai in New York have identified a new molecular mechanism by which cocaine alters the brain's reward circuits and causes addiction. Published online in PNAS by Dr. Eric J. Nestler, M.D., Ph.D., and colleagues, the preclinical research reveals how an abundant enzyme and synaptic gene affect a key reward circuit in the brain, changing the ways genes are expressed in the nucleus accumbens. The DNA itself does not change, but its "mark" activates or represses certain genes encoding synaptic proteins within the DNA. The marks indicate epigenetic changes—changes made by enzymes—that alter the activity of the nucleus accumbens. In a mouse model, the research team found that chronic cocaine administration increased levels of an enzyme called PARP-1 or poly(ADP-ribosyl)ation polymerase-1 (image). This increase in PARP-1 leads to an increase in its PAR marks at genes in the nucleus accumbens, contributing to long-term cocaine addiction. Although this is the first time PARP-1 has been linked to cocaine addiction, PARP-1 has been under investigation for cancer treatment. "This discovery provides new leads for the development of anti-addiction medications," said the study's senior author, Dr. Nestler, Nash Family Professor of Neuroscience and Director of the Friedman Brain Institute, at the Icahn School of Medicine at Mount Sinai. Dr. Nestler said that the research team is using PARP to identify other proteins regulated by cocaine. PARP inhibitors may also prove valuable in changing cocaine's addictive power. Kimberly Scobie, Ph.D., the lead investigator and postdoctoral fellow in Dr. Nestler's laboratory, underscored the value of implicating PARP-1 in mediating the brain's reward center.
Login Or Register To Read Full Story